GPT and metabolic syndrome: Laboratory results further delineate the MAFLD phenotype, showing evidence of liver injury (elevated ALT/AST and bilirubin), worse renal function (lower eGFR) (Fig 1), higher uric acid, and prominent metabolic derangements including higher fasting glucose (97.2 ± 24.9 vs. 85.2 ± 16.6 mg/dL, p = 0.006), higher HbA1c (6.2 ± 1.5% vs. 5.2 ± 0.4%, p < 0.001), increased insulin resistance (HOMA-IR 3.5 ± 3.6 vs. 1.45 ± 1.03, p < 0.001), and dyslipidemia (higher triglycerides: 161.9 ± 62.1 vs. 105 ± 48.7 mg/dL, p < 0.001 and LDL: 95.3 ± 27.8 vs. 83.8 ± 8 mg/dL, p = 0.037).